Daniel Myers - Alimera Sciences President CEO, Director

ALIM Stock  USD 3.90  0.03  0.78%   

CEO

Mr. C. Daniel Myers is NonExecutive Chairman of the Board of Alimera Sciences, Inc. He is one of our cofounders and has served as our Chief Executive Officer and as a director since the founding of our Company in 2003. Before founding our Company, Mr. Myers was an initial employee of Novartis Ophthalmics and served as its Vice President of Sales and Marketing from 1991 to 1997 and as President from 1997 to 2003 since 2019.
Age 63
Tenure 5 years
Address 6310 Town Square, Alpharetta, GA, United States, 30005
Phone678 990 5740
Webhttps://alimerasciences.com
Myers holds a B.S. in Industrial Management from Georgia Institute of Technology. Our board of directors believes that Mr. Myers should serve as a director of the Company, in light of its business and structure, because in addition to his valuable contributions to our Company in recent years, Mr. Myers has over 33 years of ophthalmic pharmaceutical experience, including over 19 years in the role of president or chief executive officer. In addition, Mr. Myers served on the board of directors of Ocular Therapeutix, Inc. from 2009 to 2012.

Alimera Sciences Management Efficiency

The company has return on total asset (ROA) of (0.0123) % which means that it has lost $0.0123 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5876) %, meaning that it created substantial loss on money invested by shareholders. Alimera Sciences' management efficiency ratios could be used to measure how well Alimera Sciences manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of March 2024, Return On Capital Employed is likely to drop to -0.01. In addition to that, Return On Assets is likely to drop to -0.14. At this time, Alimera Sciences' Total Assets are very stable compared to the past year. As of the 29th of March 2024, Non Current Assets Total is likely to grow to about 106.2 M, while Total Current Assets are likely to drop about 42.4 M.
The company currently holds 67.4 M in liabilities. Alimera Sciences has a current ratio of 1.27, suggesting that it is in a questionable position to pay out its financial obligations when due. Debt can assist Alimera Sciences until it has trouble settling it off, either with new capital or with free cash flow. So, Alimera Sciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Alimera Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Alimera to invest in growth at high rates of return. When we think about Alimera Sciences' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 4 records

CEO Age

Murthy SimhambhatlaEvolus Inc
51
Scott SmithViatris
62
David MoatazediEvolus Inc
46
Kevin GormanNeurocrine Biosciences
66
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia. Alimera Sciences operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 145 people. Alimera Sciences (ALIM) is traded on NASDAQ Exchange in USA. It is located in 6310 Town Square, Alpharetta, GA, United States, 30005 and employs 154 people. Alimera Sciences is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Alimera Sciences Leadership Team

Elected by the shareholders, the Alimera Sciences' board of directors comprises two types of representatives: Alimera Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alimera. The board's role is to monitor Alimera Sciences' management team and ensure that shareholders' interests are well served. Alimera Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alimera Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
John Snisarenko, Director
Christopher Visick, General VP
Todd Wood, President Operations
James Largent, Independent Director
Peter Pizzo, Independent Director
Calvin Roberts, Independent Director
Samer Kaba, Chief Medical Officer
Mary Szela, Director
Phil Jones, CFO
Elliot CPA, CFO Treasurer
David Burke, Vice President
Philip Ashman, Sr. VP and European Managing Director
Jason Werner, Chief Officer
David Holland, Co-Founder and Sr. VP of Sales and Marketing
Garheng Kong, Independent Director
Kenneth Green, Chief Scientific Officer and Sr. VP
Richard Eiswirth, Pres and CFO
Brian Halak, Independent Director
Daniel Myers, President CEO, Director
Charles Myers, NonEx Consultant
Mark Brooks, Independent Director
Rich Cockrell, President
David MD, Chief Specialist

Alimera Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alimera Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Alimera Sciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alimera Sciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alimera Sciences will appreciate offsetting losses from the drop in the long position's value.

Moving against Alimera Stock

  0.43MGNX MacroGenics Financial Report 14th of May 2024 PairCorr
The ability to find closely correlated positions to Alimera Sciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alimera Sciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alimera Sciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alimera Sciences to buy it.
The correlation of Alimera Sciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alimera Sciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alimera Sciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alimera Sciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Alimera Sciences is a strong investment it is important to analyze Alimera Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Alimera Sciences' future performance. For an informed investment choice regarding Alimera Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alimera Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
To learn how to invest in Alimera Stock, please use our How to Invest in Alimera Sciences guide.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Alimera Stock analysis

When running Alimera Sciences' price analysis, check to measure Alimera Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alimera Sciences is operating at the current time. Most of Alimera Sciences' value examination focuses on studying past and present price action to predict the probability of Alimera Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alimera Sciences' price. Additionally, you may evaluate how the addition of Alimera Sciences to your portfolios can decrease your overall portfolio volatility.
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Is Alimera Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alimera Sciences. If investors know Alimera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alimera Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.84)
Revenue Per Share
3.159
Quarterly Revenue Growth
0.875
Return On Assets
(0.01)
Return On Equity
(1.59)
The market value of Alimera Sciences is measured differently than its book value, which is the value of Alimera that is recorded on the company's balance sheet. Investors also form their own opinion of Alimera Sciences' value that differs from its market value or its book value, called intrinsic value, which is Alimera Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alimera Sciences' market value can be influenced by many factors that don't directly affect Alimera Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alimera Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alimera Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alimera Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.